IIT Bombay Develops Gentler T-Cell Recovery Method to Enhance CAR T-Cell Therapy Efficiency
核心洞察
Researchers from IIT Bombay and Monash University have developed a safer and more efficient method to retrieve lab-grown T-cells (搜索) from electrospun scaffolds, addressing a major bottleneck in CAR T-cell therapy manufacturing.
The new technique using accutase (搜索) enzyme instead of trypsin significantly improves T-cell survival rates and maintains functional integrity, with recovered cells forming healthier clusters essential for cell division.
The breakthrough could help make CAR T-cell therapy more accessible and cost-effective, particularly relevant as India develops its own CAR T-cell programs to provide affordable alternatives to expensive international treatments.
Researchers from the Indian Institute of Technology Bombay, in collaboration with Monash University, have developed a breakthrough method for retrieving lab-grown T-cells (搜索) that could significantly enhance the efficiency and accessibility of CAR T-cell therapy. The innovation addresses a critical manufacturing bottleneck that has limited the effectiveness of one of cancer (搜索) treatment's most promising immunotherapies.
Addressing a Critical Manufacturing Challenge
CAR T-cell therapy works by extracting T-cells (搜索) from a patient's blood, genetically modifying them in the laboratory to recognize and attack cancer (搜索) cells, multiplying them in large numbers, and then infusing them back into the patient. While the concept is straightforward, the practical implementation faces significant hurdles, particularly in the cell recovery process.
"Cell recovery sounds simple on paper, but in practice it turns out to be one of the biggest challenges," said Prof. Prakriti Tayalia from the Department of Biosciences and Bioengineering at IIT Bombay, who led the study. "Without enough healthy cells, they cannot be tested properly or delivered efficiently for therapy."
The challenge stems from the use of electrospun scaffolds—fibrous structures designed to mimic the body's natural tissue environment. These scaffolds encourage T-cells (搜索) to cluster, a vital step for their activation and proliferation. However, as T-cells move deeper into the scaffold, they become tightly lodged between the fibers, making retrieval difficult without compromising cell viability.
Revolutionary Recovery Technique
The research team's solution involves using accutase (搜索), a milder enzyme, instead of the conventional trypsin for cell recovery. The study, conducted using Jurkat T-cells (搜索) grown inside electrospun scaffolds made from polycaprolactone, demonstrated remarkable improvements in both cell survival and functionality.
Under microscopic observation, researchers found that cells actively moved into the scaffold and became tightly lodged between the fibers. Conventional flushing methods using pipettes often failed to retrieve all cells, with many remaining trapped and reducing overall cell yield.
The new approach showed that cells recovered with accutase (搜索) survived in greater numbers compared to those treated with trypsin, which led to higher cell death rates. More importantly, the recovered cells maintained their functional integrity, forming healthy T-cell clusters—an essential precursor for cell division and sustained growth after recovery.
"Harsh treatments to cells, using enzymes such as trypsin, can damage key surface proteins needed for immune signalling and activation, reducing the cell's therapeutic usefulness. Accutase (搜索) appears mild enough to avoid this problem," Tayalia explained.
Clinical and Economic Implications
The findings, published in the journal Biomaterials Science, have significant implications for CAR T-cell therapy manufacturing. For patients undergoing treatment, every step from cell extraction to reinfusion directly affects outcomes. A higher yield of viable, functional T-cells (搜索) improves the chances of a successful immune response against cancer (搜索).
The breakthrough is particularly relevant as India develops its own CAR T-cell programs, aiming to make the therapy more affordable and scalable compared to high-cost international alternatives. Improvements in cell recovery could help reduce production inefficiencies and bring down overall costs, making these advanced therapies more accessible to patients.
Future Applications and Scalability
While the research is currently laboratory-based, its implications extend far beyond immediate applications. As CAR T-cell therapies expand to treat a wider range of cancers and potentially autoimmune diseases (搜索), efficient, reproducible, and safe cell manufacturing processes will be critical for widespread adoption.
The study addresses cell retrieval as one of the most overlooked bottlenecks in immunotherapy manufacturing. By solving this fundamental challenge, the research moves the field closer to making next-generation cancer (搜索) treatments more reliable and patient-ready.
"If we want these advanced therapies to reach patients, every step matters," Prof. Tayalia emphasized. "How we grow cells, and how we retrieve them, can make a real difference."
The development represents a significant step forward in making CAR T-cell therapy more efficient and accessible, potentially transforming how these life-saving treatments are manufactured and delivered to patients worldwide.